Kolmar Introduced Treatment for Atopic Dermatitis

Following the Korea Food and Drug Administration (KFDA)’s recent approval on pharmaceutical bioequivalence of the generic drugs, Korea Kolmar announced its successful development of a medication for treatment of atopic dermatitis (AD).

Using a non-steroid based active ingredient known as bupexamac, Kolmar’s AD ointment is proven for its anti-inflammatory effect and lower occurrence rate of a...